1. India Stocks

  2. •

    Health technology

  3. •

    Pharmaceuticals: major
Strides Pharma Science Ltd

Strides Pharma Science Ltd

998.05
INR
-25.75
(-2.52%)
66.01EPS
17.12P/E
100.28BMarket Cap
Oct 29Next Earn
2012 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
2026 Y
TTM
Revenue per Share
152.09
189.94
333.13
297.24
312.53
235.44
296.67
362.81
336.73
400.49
409.88
477.3
502.11
531.97
Basic EPS, GAAP
144.3
141.85
13.14
44.73
74.26
36.25
4.06
29.96
-51.28
-22.49
-7.76
390.55
60.34
63.53
Free Cash Flow per Basic Share
22.89
14
-35.83
-44.11
-24.09
6.71
22.87
53.73
-28.73
4.93
77.04
74.38
76.22
- -
Dividend per Share
2
110.01
2.98
4.84
4.95
2
17.18
2
2.5
- -
1.49
2.5
4
- -
Book Value per Share
344.58
193.87
297.48
307.96
275.27
295.78
282.19
309.62
262.75
244.98
231.29
276.88
337.15
- -
Tangible Book Value per Share
-29.87
145.02
44.68
8.75
-8.14
-26.53
173.34
187.06
139.03
125.73
116.33
155.95
185.9
- -
Basic Weighted Avg Shares
59
60
83
89
89
90
90
90
90
90
91
92
92
92
Sales/Revenue/Turnover
8,919
11,315
27,512
26,564
27,965
21,083
26,567
32,512
30,221
36,077
37,300
43,917
46,280
49,033
Operating Margin (%)
14.28
15.83
10.47
16.19
8.88
6.56
13.79
12.96
-8
3.96
8.61
13.2
13.33
14.57
Depreciation Expense
1,095
640
1,520
1,987
1,939
1,718
1,878
2,063
2,330
2,433
2,207
1,923
2,024
2,092
Net Income, GAAP
8,462
8,450
1,085
3,997
6,645
3,246
364
2,684
-4,602
-2,026
-706
35,935
5,562
5,856
Effective Tax Rate (%)
1.54
35.83
26.43
18.48
7.11
- -
20.71
11.49
- -
- -
- -
15.92
14.08
14.92
Profit Margin (%)
94.88
74.68
3.94
15.05
23.76
15.4
1.37
8.26
-15.23
-5.62
-1.89
81.82
12.02
11.94
Working Capital
-3,864
4,429
16,236
6,880
5,867
3,889
-1,702
815
-473
2,557
932
5,102
7,219
- -
LT Debt
7,311
2,548
26,285
16,377
15,591
18,149
8,577
10,928
10,221
13,435
7,431
6,227
6,042
- -
Total Equity
20,981
11,697
27,081
28,874
26,183
28,017
25,947
28,140
23,833
21,729
20,717
25,865
31,493
- -
Return on Invested Capital (%)
2.58
3.8
4.4
5.34
3.59
- -
2.6
7.84
- -
- -
- -
12.47
11.33
- -
Return on Capital (%)
23.69
30.14
5.77
7.71
13.97
- -
1.22
7.94
- -
- -
- -
83.14
14.23
- -
Return on Common Equity (%)
49.81
53.11
5.69
14.77
25.47
12.7
1.41
10.12
-17.92
-8.87
-3.26
153.65
19.66
- -

Capital Structure

INR

•

in mil. unless spec.
Dec'26
Mar'26
Jun'27
ST Debt
- -
11,538
- -
LT Borrowings
- -
5,523
- -
LT Finance Leases
- -
518
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
92
92
92
Market Capitalization
83,172
86,435
100,279

Working Capital

INR

•

in mil. unless spec.
Dec'26
Mar'26
Jun'27
Total Current Assets
- -
36,174
- -
Cash, Cash Equivalents & STI
- -
2,045
- -
Accounts Receivable, Net
- -
12,890
- -
Inventories
- -
16,348
- -
Total Current Liabilities
- -
28,955
- -
Payables & Accruals
- -
- -
- -
ST Debt
- -
11,538
- -
Deferred Revenue
- -
- -
- -

Growth Rates

INR

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
2.32%
3.56%
21.76%
Free Cash Flow
144.42%
241.61%
2.65%
Net Income, GAAP
-483.38%
-1,133.22%
-84.52%
Sales/Revenue/Turnover
6.44%
7.77%
5.38%
Total Cash Common Dividend
- -
- -
60.35%

Quarterly Revenue

INR

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
10,543
11,669
11,537
11,904
43,917
2026
11,197
- -
11,946
13,235
46,280
2027
12,654
- -
- -
- -
- -

Quarterly Earnings Per Share

INR

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
364.65
7.81
9.56
8.92
390.55
2026
10.81
- -
21.93
13.77
60.34
2027
17.02
- -
- -
- -
- -

Quarterly Dividends Per Share

INR

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
- -
- -
- -
- -
2.5
2026
- -
- -
- -
- -
4
2027
- -
- -
- -
- -
- -

Company Description

Company Profile APIChatGPT
CEO
Badree Komandur
Full Time Employees
5,394
Sector
Health technology
Industry
Pharmaceuticals: major
Address
Strides House Bangalore KA India 560076
IPO Date
Feb 3, 2000
Website
strides.com
Similar Companies
Eli Lilly and Company (NYSE:LLY)
Novo Nordisk A/S (NYSE:NVO)
Johnson & Johnson (NYSE:JNJ)
Pfizer, Inc. (NYSE:PFE)
Dr. Reddy's Laboratories Ltd. (NSE:DRREDDY)
Divi's Laboratories Limited (NSE:DIVISLAB)
Business
Strides Pharma Science Limited, headquartered in Bengaluru, India and founded in 1990, develops and manufactures a broad portfolio of pharmaceutical products including niche generic formulations, soft gelatin capsules, hard gelatin capsules, tablets, ointments, dry and wet injectables, over-the-counter drugs and nutraceuticals; it specializes in IP-led finished dosage forms across therapeutic categories such as anti-emetics, cardiovascular, dermatology, anti-infectives and opioids for regulated markets including the United States, Europe, Australia and emerging markets. The company operates manufacturing facilities across four continents with eight sites in India, facilities in the United States, Italy and Kenya, and maintains marketing presence in over 100 countries through partnerships with generic firms for retail and hospital supply of injectables and softgels. Subsidiaries include Strides Pharma Inc. in the USA, Beltapharm S.r.l. in Italy and Universal Corporation Limited in Kenya. In April 2025, Strides acquired four approved Abbreviated New Drug Applications (ANDAs) from Nostrum Laboratories for the US market valued at approximately USD 57 million for USD 2.075 million, planning launches of two commercial products within 12 months; recent financials reflect Q2 FY2026 revenue growth of 4.6% year-over-year, EBITDA up 25.4% and operational PAT up 84%, targeting USD 400 million US revenue by FY2028.